Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, with a specific reporting date of July 5, 2022. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) through a dividend reinvestment plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £17.6572 per share.
- Transaction Date: July 1, 2022.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details routine share acquisitions resulting from the reinvestment of dividends paid on July 1, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of insider trading activity compliant with reporting rules.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of shares via dividend reinvestment, not open market purchases or sales.
- Participants: Transactions involved Ms. S. Jackson (SVP, Global Communications), Mr. D. Jackson (PCA), Ms. V. Whyte (Company Secretary), Mr. I. Whyte (PCA), and Ms. D. Connor (PCA of President, Vaccines and Global Health).
- Volume: Total shares acquired across all listed individuals ranged from 8 to 843 shares per transaction.
- Financial Data Limitation: This filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F or earnings releases for those metrics.